Current treatment of nontuberculous mycobacteriosis: An update

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 7, 2012, Pages 967-986

  Esteban, Jaime ^a   García Pedrazuela, María ^a   Muñoz Egea, María Carmen ^a   Alcaide, Fernando ^b,c  

^a UAM)   (Spain)

^b IDIBELL Bellvitge Hospital   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Management; Mycobacteriosis; Nontuberculous mycobacteria; Therapy; Treatment

Indexed keywords

AMIKACIN; AZITHROMYCIN; BCG VACCINE; CEFOXITIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DOXYCYCLINE; ETHAMBUTOL; GATIFLOXACIN; HEAT SHOCK PROTEIN 65; IMIPENEM; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ABSCESS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ATYPICAL MYCOBACTERIOSIS; BACTERIUM ISOLATE; BIOFILM; DEBRIDEMENT; DRUG EFFICACY; DRUG SAFETY; EXCISION; FOLLICULITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM GENAVENSE; MYCOBACTERIUM HAEMOPHILUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MALMOENSE; MYCOBACTERIUM MARINUM; MYCOBACTERIUM SCROFULACEUM; MYCOBACTERIUM SIMIAE; MYCOBACTERIUM SZULGAI; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM ULCERANS; MYCOBACTERIUM XENOPEI; RESPIRATORY DISTRESS; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS;

EID: 84860177790     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.677824     Document Type: Review

References (165)

1. Wayne LG, Kubica GP. Genus Mycobacterium lehman and neumann 1896. In: Sneath PHA, Mair NS, Sharpe ME, Holt JG, editors. Bergey's Manual of Systematic Bacteriology. 1st edition. Williams & Wilkins; Baltimore: 1986. p. 1436-57
2. Euzeby JP. List of Prokaryotic names with standing in nomenclature-genus Mycobacterium. 30 december 2011; Available from: http://www.bacterio.cict. fr/m/mycobacterium.html
3. Falkinham JO III. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009;107(2):356-67
4. Falkinham JO III. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis 2011;17(3):419-24
5. CLSI. Susceptibility testing of Mycobacteria, nocardiae, and other aerobic actinomycetes; aprproved standard. In: CLSI, editor. 2nd edition. CLSI; Wayne, PA: 2011
6. Arend SM, van Soolingen D, Ottenhoff TH. Diagnosis and treatment of lung infection with nontuberculous mycobacteria. Curr Opin Pulm Med 2009;15(3):201-8
7. Griffith DE. Nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2010;23(2):185-90
8. McGrath EE, Blades Z, McCabe J, et al. Nontuberculous mycobacteria and the lung: from suspicion to treatment. Lung 2010;188(4):269-82
9. McGrath EE, McCabe J, Anderson PB, et al. Guidelines on the diagnosis and treatment of pulmonary non-tuberculous mycobacteria infection. Int J Clin Prac 2008;62(12):1947-55 but also rapidly growing NTM, and the treatments in each case.
10. Esteban J, Ortiz-Perez A. Current treatment of atypical mycobacteriosis. Expert Opin Pharmacother 2009;10(17):2787-99
11. van Ingen J, Boeree MJ, Kosters K, et al. Proposal to elevate Mycobacterium avium complex ITS sequevar MAC-Q to Mycobacterium vulneris sp. nov. Int J Syst Evol Microbiol 2009;59(Pt 9):2277-82
12. Ben Salah I, Cayrou C, Raoult D, et al. Mycobacterium marseillense sp. nov., Mycobacterium timonense sp. nov. and Mycobacterium bouchedurhonense sp. nov., novel species in the Mycobacterium avium complex. Int J Syst Evol Microbiol 2009. [Epub ahead of print]
13. Williams MM, Yakrus MA, Arduino MJ, et al. Structural analysis of biofilm formation by rapidly and slowly growing nontuberculous mycobacteria. Appl Environ Microbiol 2009;75(7):2091-8
14. Behr MA, Falkinham JO III. Molecular epidemiology of nontuberculous mycobacteria. Future Microbiol 2009;4(8):1009-20
15. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clin Microbiol Infect 2009;15(10):906-10
16. Yew WW, Sotgiu G, Migliori GB. Update in tuberculosis and nontuberculous mycobacterial disease 2010. Am J Respir Crit Care Med 2011;184(2):180-5
17. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008;178(10):1066-74
18. Amir J. Non-tuberculous mycobacterial lymphadenitis in children: diagnosis and management. Isr Med Assoc J 2010;12(1):49-52
19. Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis 2009;15(9):1351-8; quiz 544
20. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009;15(10):1556-61
21. Simons S, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 2011;17(3):343-9
22. Elston D. Nontuberculous mycobacterial skin infections: recognition and management. Am J Clin Dermatol 2009;10(5):281-5
23. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175(4):367-416
24. van Ingen J, van der Laan T, Dekhuijzen R, et al. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands. Int J Antimicrob Agents 2010;35(2):169-73
25. Deshpande D, Srivastava S, Meek C, et al. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother 2010;54(6):2534-9
26. Sim YS, Park HY, Jeon K, et al. Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease. Yonsei Med J 2010;51(6):888-94
27. Jenkins PA, Campbell IA, Banks J. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in the treatment of opportunist mycobacterial diseases and an assessment of the value of immunotherapy by The British Thoracic Society. Thorax 2008;63:627-34 (Pubitemid 351969257)
28. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003;124(4):1482-6 (Pubitemid 37290061)
29. Griffith DE. Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Drug Saf 1999;21(2):137-52 (Pubitemid 29389173)
30. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58(RR-4):1-207; quiz CE1-4
31. Deshpande D, Srivastava S, Meek C, et al. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother 2010;54(5):1728-33
32. Martin-Casabona N, Bahrmand AR, Bennedsen J, et al. Nontuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberculosis Lung Dis 2004;8(10):1186-93 (Pubitemid 39371831)
33. Bittner MJ, Horowitz EA, Safranek TJ, et al. Emergence of Mycobacterium kansasii as the leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital. Clin Infect Dis 1996;22(6):1109-10 (Pubitemid 26260626)
34. Falkinham JO III. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996;9(2):177-215
35. Bloch KC, Zwerling L, Pletcher MJ, et al. Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study. Ann Intern Med 1998;129(9):698-704 (Pubitemid 28507142)
36. Santin M, Alcaide F, Benitez MA, et al. Incidence and molecular typing of Mycobacterium kansasii in a defined geographical area in Catalonia, Spain. Epidemiol Infect 2004;132(3):425-32 (Pubitemid 38714118)
37. Alcaide F, Richter I, Bernasconi C, et al. Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. J Clin Microbiol 1997;35(8):1959-64 (Pubitemid 27318686)
38. Picardeau M, Prod'Hom G, Raskine L, et al. Genotypic characterization of five subspecies of Mycobacterium kansasii. J Clin Microbiol 1997;35(1):25-32 (Pubitemid 26422623)
39. Richter E, Niemann S, Rusch-Gerdes S, et al. Identification of Mycobacterium kansasii by using a DNA probe (AccuProbe) and molecular techniques. J Clin Microbiol 1999;37(4):964-70 (Pubitemid 29140598)
40. Taillard C, Greub G, Weber R, et al. Clinical implications of Mycobacterium kansasii species heterogeneity: swiss National Survey. J Clin Microbiol 2003;41(3):1240-4 (Pubitemid 36307134)
41. Zhang Y, Mann LB, Wilson RW, et al. Molecular analysis of Mycobacterium kansasii isolates from the United States. J Clin Microbiol 2004;42(1):119-25 (Pubitemid 38082708)
42. Griffith DE. Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis 2007;20(2):198-203 (Pubitemid 46340804)
43. Santin M, Alcaide F. Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy. Int J Tuberculosis Lung Dis 2003;7(7):673-7 (Pubitemid 36806863)
44. Witzig RS, Fazal BA, Mera RM, et al. Clinical manifestations and implications of coinfection with Mycobacterium kansasii and human immunodeficiency virus type 1. Clin Infect Dis 1995;21(1):77-85
45. Sun Z, Zhang Y. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother 1999;43(3):537-42 (Pubitemid 29109516)
46. Ahn CH, Lowell JR, Ahn SS, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983;128(6):1048-50 (Pubitemid 14207103)
47. Research-Committee-British- Thoracic-Society. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax 1994;49(5):442-5
48. Sauret J, Hernandez-Flix S, Castro E, et al. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. Tuber Lung Dis 1995;76(2):104-8
49. Kaustova J, Chmelik M, Ettlova D, et al. Disease due to Mycobacterium kansasii in the Czech Republic: 1984-89. Tuber Lung Dis 1995;76(3):205-9
50. Santin M, Dorca J, Alcaide F, et al. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J 2009;33(1):148-52
51. Alcaide F, Calatayud L, Santin M, et al. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004;48(12):4562-5 (Pubitemid 39577654)
52. Wallace RJ Jr, Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis 1994;18(5):736-43 (Pubitemid 24145906)
53. Klein JL, Brown TJ, French GL. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob Agents Chemother 2001;45(11):3056-8 (Pubitemid 32988827)
54. Fassbender M, Lode H, Schiller C, et al. Comparative pharmacokinetics of macrolide antibiotics and concentrations achieved in polymorphonuclear leukocytes and saliva. Clin Microbiol Infect 1996;1(4):235-43 (Pubitemid 126682660)
55. Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin. Drugs Today (Barc) 2000;36(4):229-44 (Pubitemid 30176463)
56. Conte JE Jr, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46(5):1475-80 (Pubitemid 34415331)
57. Cynamon MH, Elliott SA, DeStefano MS, et al. Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection. J Antimicrob Chemother 2003;52(2):306-7 (Pubitemid 36986899)
58. Brown-Elliott BA, Crist CJ, Mann LB, et al. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother 2003;47(5):1736-8 (Pubitemid 36548563)
59. Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003;37(9):1178-82 (Pubitemid 37372505)
60. Tompkins JC, Witzig RS. Mycobacterium kansasii in HIV patients: clarithromycin and antiretroviral effects. Int J Tuberculosis Lung Dis 2007;11(3):331-7 (Pubitemid 46447443)
61. Johnson PD, Azuolas J, Lavender CJ, et al. Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis 2007;13(11):1653-60 (Pubitemid 350126191)
62. Portaels F, Meyers WM, Ablordey A, et al. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis 2008;2(3):e178
63. Sarfo FS, Phillips R, Asiedu K, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010;54(9):3678-85
64. Nakanaga K, Hoshino Y, Yotsu RR, et al. Nineteen cases of Buruli ulcer diagnosed in Japan from 1980 to 2010. J Clin Microbiol 2011;49(11):3829-36
65. Debacker M, Aguiar J, Steunou C, et al. Buruli ulcer recurrence, Benin. Emerg Infect Dis 2005;11(4):584-9 (Pubitemid 40462909)
66. Beissner M, Awua-Boateng NY, Thompson W, et al. A genotypic approach for detection, identification, and characterization of drug resistance in Mycobacterium ulcerans in clinical samples and isolates from Ghana. Am J Trop Med Hyg 2010;83(5):1059-65
67. Organization WH. Buruli ulcer meetings in Cotonou, Benin. 2009. Available from: http://www.who. int/buruli/archives/en/index.html [Cited 13 December 2011]
68. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010;375(9715):664-72
69. Gordon CL, Buntine JA, Hayman JA, et al. All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS Negl Trop Dis 2010;4(11):e770
70. O'Brien DP, McDonald A, Callan P, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis 2012;6(1):e1473
71. Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45(8):1001-7 (Pubitemid 47580349)
72. Alvarez-Uria G. Lung disease caused by nontuberculous mycobacteria. Curr opin Pulm Med 2010;16(3):251-6
73. Andrejak C, Lescure FX, Pukenyte E, et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 2009;64(4):291-6
74. Danesh-Clough T, Theis JC, van der Linden A. Mycobacterium xenopi infection of the spine: a case report and literature review. Spine (Phila Pa 1976 2000;25(5):626-8 (Pubitemid 30158223)
75. Salliot C, Desplaces N, Boisrenoult P, et al. Arthritis due to Mycobacterium xenopi: a retrospective study of 7 cases in France. Clin Infect Dis 2006;43(8):987-93 (Pubitemid 44631097)
76. Sanchez R, Font B, Pi J. Mycobacterium xenopi flexor tenosynovitis. J Hand Surg Eur Vol 2010;35(6):516-17
77. Satyanarayana G, Heysell SK, Scully KW, et al. Mycobacterial infections in a large Virginia hospital, 2001-2009. BMC Infect Dis 2011;11:113
78. Phyffer GE. Mycobacterium: general characteristics, laboratory detection, and staining procedures. In: Murray PR, Baron EJ, Jorgensen JM, Landry ML, Phaller MA, editors. Manual of Clinical Microbiology. 9th edition. ASM Press; Washington, D.C: 2010. p. 543-72
79. Duarte JN, Marques N, Barroso L, et al. Cervical abscess in an immunocompetent patient with Mycobacterium malmoense pulmonary disease. Oral Maxillofac Surg 2011; [Epub ahead of print] doi: 10.1007/s10006-011-0306-5
80. Hoefsloot W, van Ingen J, de Lange WC, et al. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J 2009;34(4):926-31
81. Abgueguen P, Rabier V, Mahaza C, et al. Mycobacterium malmoense: an underestimated nontuberculous mycobacterium. Diagn Microbiol Infect Dis 2010;66(1):98-100
82. Claesson G, Bennet R, Eriksson M, et al. Nerve dysfunction following surgical treatment of cervical non-tuberculous mycobacterial lymphadenitis in children. Acta Paediatr 2011;100(2):299-302
83. Tortoli E, Mattei R, Russo C, et al. Mycobacterium lentiflavum, an emerging pathogen? J Infect 2006;52(6):e185-7 (Pubitemid 43811970)
84. van Ingen J, Totten SE, Heifets LB, et al. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 2012;39(2):173-6
85. Philip J, Bhatia S, Sugar A, et al. Mycobacterium lentiflavum-a cause of infections in the head and neck: case report and literature review. J Oral Maxillofac Surg 2011;69(4):1114-16
86. Niobe SN, Bebear CM, Clerc M, et al. Disseminated Mycobacterium lentiflavum infection in a human immunodeficiency virus-infected patient. J Clin Microbiol 2001;39(5):2030-2 (Pubitemid 32417073)
87. Marshall HM, Carter R, Torbey MJ, et al. Mycobacterium lentiflavum in drinking water supplies, Australia. Emerg Infect Dis 2011;17(3):395-402
88. Conger NG, O'Connell RJ, Laurel VL, et al. Mycobacterium simae outbreak associated with a hospital water supply. Infect Control Hosp Epidemiol 2004;25(12):1050-5 (Pubitemid 39664731)
89. van Ingen J, Boeree MJ, Dekhuijzen PN, et al. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur Respir J 2008;31(1):106-9
90. Narang R, Narang P, Jain AP, et al. Disseminated disease caused by Mycobacterium simiae in AIDS patients: a report of three cases. Clin Microbiol Infect 2010;16(7):912-14
91. Charles P, Lortholary O, Dechartres A, et al. Mycobacterium genavense infections: a retrospective multicenter study in France, 1996-2007. Medicine (Baltimore) 2011;90(4):223-30
92. Thomsen VO, Dragsted UB, Bauer J, et al. Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists. J Clin Microbiol 1999;37(12):3901-5
93. Rammaert B, Couderc LJ, Rivaud E, et al. Mycobacterium genavense as a cause of subacute pneumonia in patients with severe cellular immunodeficiency. BMC Infect Dis 2011;11:311
94. Doggett JS, Strasfeld L. Disseminated Mycobacterium genavense with pulmonary nodules in a kidney transplant recipient: case report and review of the literature. Transpl Infect Dis 2011;13(1):38-43
95. Bogdan C, Kern P, Richter E, et al. Systemic infection with Mycobacterium genavense following immunosuppressive therapy in a patient who was seronegative for human immunodeficiency virus. Clin Infect Dis 1997;24(6):1245-7 (Pubitemid 27249033)
96. Sompolinsky D, Lagziel A, Rosenberg I. Further studies of a new pathogenic mycobacterium (M. haemophilum sp. nov.). Can J Microbiol 1979;25(2):217-26 (Pubitemid 9133867)
97. Dawson DJ, Jennis F. Mycobacteria with a growth requirement for ferric ammonium citrate, identified as Mycobacterium haemophilum. J Clin Microbiol 1980;11(2):190-2 (Pubitemid 10169140)
98. Saubolle MA, Kiehn TE, White MH, et al. Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev 1996;9(4):435-47 (Pubitemid 26366531)
99. Shah MK, Sebti A, Kiehn TE, et al. Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis 2001;33(3):330-7 (Pubitemid 32664836)
100. Lindeboom JA, Prins JM, Bruijnesteijn van Coppenraet ES, et al. Cervicofacial lymphadenitis in children caused by Mycobacterium haemophilum. Clin Infect Dis 2005;41(11):1569-75 (Pubitemid 41691594)
101. Cohen YH, Amir J, Ashkenazi S, et al. Mycobacterium haemophilum and lymphadenitis in immunocompetent children, Israel. Emerg Infect Dis 2008;14(9):1437-9
102. Lindeboom JA, Bruijnesteijn van Coppenraet LE, van Soolingen D, et al. Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev 2011;24(4):701-17
103. Minani TJ, Saubolle MA, Yu E, et al. Mycobacterium haemophilum as a novel etiology of cervical lymphadenitis in an otherwise healthy adult patient. J Clin Microbiol 2010;48(7):2636-9
104. Bicmen C, Coskun M, Gunduz AT, et al. Nontuberculous mycobacteria isolated from pulmonary specimens between 2004 and 2009: causative agent or not? New Microbiol 2010;33(4):399-403
105. Maloney JM, Gregg CR, Stephens DS, et al. Infections caused by Mycobacterium szulgai in humans. Rev Infect Dis 1987;9(6):1120-6
106. Marks J, Jenkins PA, Tsukamura M. Mycobacterium szulgai-a new pathogen. Tubercle 1972;53(3):210-14
107. Krusche-Mandl I, Decramer A, Boltuch-Sherif J, et al. Non-tuberculous mycobacterial infections of the hand and wrist: a retrospective review of five cases from a single centre. Handchir Mikrochir Plast Chir 2009;41(5):283-7
108. Ohta H, Miyauchi E, Ebina M, et al. A case of cutaneous infection caused by mycobacterium szulgai with progression to acute respiratory distress syndrome. Clin Med Insights Case Rep 2011;4:29-33
109. Meyer JJ, Gelman SS. Multifocal osteomyelitis due to Mycobacterium szulgai in a patient with chronic lymphocytic leukemia. J Infect 2008;56(2):151-4
110. van Ingen J, Boeree MJ, de Lange WC, et al. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis 2008;46(8):1200-5 (Pubitemid 351589903)
111. Sanchez-Alarcos JM, De Miguel-Diez J, Bonilla I, et al. Pulmonary infection due to Mycobacterium szulgai. Respiration 2003;70(5):533-6 (Pubitemid 37524122)
112. Kim HY, Kim BJ, Kook Y, et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010;54(6):347-53
113. Leao SC, Tortoli E, Euzeby JP, et al. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011;61(Pt 9):2311-13
114. De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006;42(12):1756-63 (Pubitemid 43839444)
115. Set R, Shastri J. Laboratory aspects of clinically significant rapidly growing mycobacteria. Indian J Med Microbiol 2011;29(4):343-52
116. Brown-Elliot BA, Wallace RJ Jr. Rapidly Growing Mycobacteria. In: Schlossberg D, editor. Tuberculosis and Nontuberculous Mycobacterial Infections. 6th edition. ASM Press; Washington, D.C: 2011. p. 565-77
117. Regnier S, Cambau E, Meningaud JP, et al. Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin Infect Dis 2009;49(9):1358-64
118. van Dissel JT, Kuijper EJ. Rapidly growing mycobacteria: emerging pathogens in cosmetic procedures of the skin. Clin Infect Dis 2009;49(9):1365-8
119. Bechara C, Macheras E, Heym B, et al. Mycobacterium abscessus skin infection after tattooing: first case report and review of the literature. Dermatology 2010;221(1):1-4
120. Rodriguez-Blanco I, Fernandez LC, Suarez-Penaranda JM, et al. Mycobacterium chelonae infection associated with tattoos. Acta Derm Venereol 2011;91(1):61-2
121. Brown-Elliott BA, Wallace RJ Jr, Tichindelean C, et al. A five year community/hospital outbreak of Mycobacterium porcinum related to public water supplies. J Clin Microbiol 2011;49(12):4231-8
122. Esteban J, Martin-de-Hijas NZ, Fernandez AI, et al. Epidemiology of infections due to non-pigmented rapidly growing Mycobacteria diagnosed in an urban area. Eur J Clin Microbiol 2008;27(10):951-7
123. Nessar R, Cambau E, Reyrat JM, et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012;67(4):810-8
124. Esteban J, Martin-de-Hijas NZ, Garcia-Almeida D, et al. Prevalence of erm methylase genes in clinical isolates of nonpigmented, rapidly growing mycobacteria. Clin Microbiol Infect 2009;15(10):919-23
125. Esteban J, Martin-de-Hijas NZ, Ortiz-Perez A, et al. Detection of lfrA and tap efflux pump genes among clinical isolates of non-pigmented rapidly growing mycobacteria. Int J Antimicrob Agents 2009;34(5):454-6
126. Nash KA, Andini N, Zhang Y, et al. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother 2006;50(10):3476-8 (Pubitemid 44527531)
127. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009;53(4):1367-76
128. Nessar R, Reyrat JM, Murray A, et al. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J Antimicrob Chemother 2011;66(8):1719-24
129. Esteban J, Gadea I, Torres MV, et al. A comparison between disk diffusion and microdilution for susceptibility testing of Mycobacterium fortuitum complex. J Chemother 2002;14(6):547-53 (Pubitemid 36135408)
130. Fernandez-Roblas R, Esteban J, Cabria F, et al. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. Antimicrob Agents Chemother 2000;44(1):181-2 (Pubitemid 30010693)
131. Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45(3):764-7 (Pubitemid 32182022)
132. Fernandez-Roblas R, Martin-de-Hijas NZ, Fernandez-Martinez AI, et al. In vitro activity of tigecycline and 10 other antimicrobials against non-pigmented rapidly growing mycobacteria. Antimicrob Agents Chemother 2008;52(11):4184-6
133. Wallace RJJ, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002;46(10):3164-7
134. Bastian S, Brossier F, Wichlacz C, et al. Daptomycin is not active against rapidly growing mycobacteria. J Med Microbiol 2010;59(Pt 1):135-6
135. Griffith DE. The talking Mycobacterium abscessus blues. Clin Infect Dis 2011;52(5):572-4
136. Uyan ZS, Ersu R, Oktem S, et al. Mycobacterium abscessus infection in a cystic fibrosis patient: a difficult to treat infection. Int J Tuberculosis Lung Dis 2010;14(2):250-1
137. van Ingen J, de Zwaan R, Dekhuijzen RP, et al. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect 2009;59(5):324-31
138. Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011;52(5):565-71
139. Wallace RJ Jr, Brown-Elliott BA, Wilson RW, et al. Clinical and laboratory features of Mycobacterium porcinum. J Clin Microbiol 2004;42(12):5689-97 (Pubitemid 39664354)
140. Patil R, Patil T, Schenfeld L, et al. Mycobacterium porcinum peritonitis in a patient on continuous ambulatory peritoneal dialysis. J Gen Intern Med 2011;26(3):346-8
141. Sakuramoto Y, Goto K, Okamoto K, et al. Mycobacterium marinum infection causing extensive cutaneous ulcerations and deep abscesses on the extremities: a case report. Nippon Naika Gakkai Zasshi 2010;99(4):831-3
142. El Amrani MH, Adoui M, Patey O, et al. Upper extremity Mycobacterium marinum infection. Orthop Traumatol Surg Res 2010;96(6):706-11
143. Savini H, Morel F, Vedy S, et al. Sporotrichoid topographic distribution and Mycobacterium marinum grown on a subdermal contraceptive implant. Rev Med Interne 2011;32(4):e49-51
144. Salik D, Del Marmol V. Refractory hand ulceration: a case of chronic ulceration and sporotrichoid spread in a fish tank hobbyist following Mycobacterium marinum infection. Case Rep Dermatol 2011;3(2):137-41
145. Giordano CN, Kalb RE, Brass C, et al. Nodular lymphangitis: report of a case with presentation of a diagnostic paradigm. Dermatol Online J 2010;16(9):1
146. Zeegelaar JE, Faber WR. Imported tropical infectious ulcers in travelers. Am J Clin Dermatol 2008;9(4):219-32 (Pubitemid 351892370)
147. Streit M, Bohlen LM, Hunziker T, et al. Disseminated Mycobacterium marinum infection with extensive cutaneous eruption and bacteremia in an immunocompromised patient. Eur J Dermatol 2006;16(1):79-83 (Pubitemid 43224079)
148. Tran H, Kamino H, Walters RF. Mycobacterium marinum infection. Dermatol Online J 2008;14(10):7
149. Aubry A, Jarlier V, Escolano S, et al. Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob Agents Chemother 2000;44(11):3133-6
150. Nenoff P, Klapper BM, Mayser P, et al. Infections due to Mycobacterium marinum: a review. Hautarzt 2011;62(4):266-71
151. Osorio F, Magina S, Carvalho T, et al. Mycobacterium marinum skin infection with tenosynovitis successfully treated with doxycycline. Dermatol Online J 2010;16(9):7
152. Dolenc-Voljc M, Zolnir-Dovc M. Delayed diagnosis of Mycobacterium marinum infection: a case report and review of the literature. Acta Dermatovenerol Alp Panonica Adriat 2010;19(2):35-9
153. Brown BA, Wallace RJJ, Onyi GO. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 1992;36(9):1987-90
154. Parrish N, Luethke R, Dionne K, et al. Case of Mycobacterium marinum infection with unusual patterns of susceptibility to commonly used antibiotics. J Clin Microbiol 2011;49(5):2056-8
155. Cummins DL, Delacerda D, Tausk FA. Mycobacterium marinum with different responses to second-generation tetracyclines. Int J Dermatol 2005;44(6):518-20 (Pubitemid 40867563)
156. Zambrano MM, Kolter R. Mycobacterial biofilms: a greasy way to hold it together. Cell 2005;123(5):762-4 (Pubitemid 41721023)
157. Pang JM, Layre E, Sweet L, et al. The polyketide Pks1 contributes to biofilm formation in Mycobacterium tuberculosis. J Bacteriol 2012;194(3):715-21
158. Fux CA, Stoodley P, Hall-Stoodley L, et al. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther 2003;1(4):667-83 (Pubitemid 38855130)
159. Costerton JW. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol 2001;9(2):50-2 (Pubitemid 32155317)
160. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15(2):167-93 (Pubitemid 34303762)
161. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004;2(2):95-108 (Pubitemid 39490064)
162. Esteban J, Martin-de-Hijas NZ, Kinnari TJ, et al. Biofilm development by potentially pathogenic non-pigmented rapidly growing mycobacteria. BMC Microbiol 2008;8:184
163. Martin-de-Hijas NZ, Garcia-Almeida D, Ayala G, et al. Biofilm development by clinical strains of non-pigmented rapidly growing mycobacteria. Clin Microbiol Infect 2009;15(10):931-6
164. Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to planktonic bacteria. Antimicrob Agents Chemother 2008;52(6):2019-26 (Pubitemid 351758538)
165. Ortiz-Perez A, Martin-de-Hijas N, Alonso-Rodriguez N, et al. Importance of antibiotic penetration in the antimicrobial resistance of biofilm formed by non-pigmented rapidly growing mycobacteria against amikacin, ciprofloxacin and clarithromycin. Enferm Infecc Microbiol Clin 2011;29(2):79-84